CA-LEVITASBIO
7.11.2022 13:54:36 CET | Business Wire | Press release
LevitasBio, Inc., www.levitasbio.com, a premier end-to-end sample processing and analysis provider to the life sciences market, announced it has completed Series C round financing of $35 million to advance its mission of providing powerful, industry-leading methods of cellular analysis.
The funding allows LevitasBio to accelerate its commercial success through the development of next generation high-throughput instruments for sample processing and analysis. For the first time ever, researchers using LevitasBio’s groundbreaking technology can examine, analyze and understand true biological signatures without altering, stressing, or damaging cells—all while preserving the original samples.
This new round of funding was led by Novalis Lifesciences with the participation of Pavilion Capital—a unit of Temasek Holdings Pte, an industry-leading strategic investor, and was supported by existing investor Decheng Capital.
“This funding furthers our plans to become the benchmark platform for sample processing workflows,” stated Joe Walthers, LevitasBio VP of Finance. “Our existing life sciences and pharmaceutical development clients overwhelmingly validated the power and success of our technology.”
"Novalis is excited to support LevitasBio as it transforms sample processing and analysis. This critical part of the workflow has stymied industry innovation and is underappreciated by the investment community,” said Paul Meister, Partner at Novalis LifeSciences. "We are impressed with LevitasBio's unique solutions that have been commercialized thus far and, with our investment, will enable their revolutionary advancement of sample preparation and analysis that powers life science research.''
Over the last year LevitasBio expanded its impressive portfolio with multiple product developments:
- LeviPrep—novel and empowering cold tissue dissociation kits
- LeviSelect—specific surface marker enrichment assays
- LeviCell EOS System—next generation sample processing platform with higher throughput and temperature control
- LeviMetrics—integrated analysis software for real-time on-platform analysis
Martin Pieprzyk, CEO of LevitasBio, expounded that “Unlike current industry methods that induce alterations, stress or damage that mask the true biology of your sample, LevitasBio solutions preserve the key biological signatures that deliver the most viable and unaltered cells, providing researchers clearer data for actionable insights. I believe LevitasBio is expertly positioned to become the de facto industry standard for cellular analysis.”
LevitasBio—True Biology Begins Here
Our mission is to advance science and human health by providing researchers with new and powerful methods of cellular analysis. LevitasBio delivers the first truly novel approach to cellular analysis in 30 years. Our proprietary label-free levitation technology enables researchers to rescue and achieve higher quality and quantity of cells without introducing bias, high pressure, or modifications to gene expression profiles, ensuring the integrity of downstream data and analysis is maintained.
About Novalis LifeSciences LLC
Novalis LifeSciences is an investment and advisory firm for the Life Science industry that was founded in 2017 by Marijn E. Dekkers. With a team of experienced operating executives from the Life Science industry, Novalis funds and advises visionary Life Science entrepreneurs. In addition to making financial investments, Novalis provides strategic and operational advice to portfolio companies that are at a critical growth stage in their development. The firm has approximately $500M in assets under management in two investment funds.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221107005087/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Arc'teryx Appoints Avery Baker Chief Brand Officer27.1.2026 15:00:00 CET | Press release
Technical apparel and equipment brand appoints first-ever Chief Brand Officer and names Tobia Prevedello General Manager, EMEA Arc'teryx Equipment, the global design company specializing in technical high-performance apparel and equipment, today announced the appointment of Avery Baker as its first-ever Chief Brand Officer, a newly created executive role that marks a significant step in the company’s global evolution. Baker joins Arc’teryx as it continues to unlock brand potential, elevate global capabilities, and fuel long-term growth across North America, EMEA, APAC, and Greater China. Additionally, Tobia Prevedello was appointed General Manager, EMEA, bringing more than 20 years of international leadership experience across EMEA and APAC. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260127462809/en/ Avery Baker, Chief Brand Officer As Chief Brand Officer, Baker will report to CEO Stuart Haselden and will lead global bra
Research From Lenovo Reveals AI Is Paying Off, Yet Most CIOs Aren’t Ready for What Comes Next27.1.2026 15:00:00 CET | Press release
CIOs anticipate up to 179% ROI on AI investments, with further efficiencies expected as Agentic AI scalesMore than half of organizations (60%) are in late-stage AI adoption – though only 27% have a comprehensive governance framework in placeOnly 21% of CIOs use Agentic AI today, with half (55%) exploring or piloting use casesHybrid AI emerges as preferred deployment model, used by almost two thirds (62%) Enterprises have moved decisively from AI pilots to scaled implementations, driven by proven benefits and expectations of significant financial returns, according to Lenovo CIO Playbook 2026 with research insights by IDC. Nearly half (46%) of AI proof-of-concepts have already progressed into production, with some organizations projecting returns of $2.79 for every dollar invested. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260127255538/en/ Lenovo CIO Playbook 2026: The Race for Enterprise AI AI is now recognized as a cor
Ypê Deepens Partnership with Rimini Street to Accelerate Agentic AI and Maximize ERP Value27.1.2026 15:00:00 CET | Press release
Powered by Rimini Support™ for SAP and Rimini Agentic UX™, Ypê turns ERP stability into a launchpad for rapid, enterprise-wide Agentic AI innovation Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™, and the leading third-party support provider for Oracle, SAP and VMware software, today announced the expansion of its partnership with Ypê, the Brazilian consumer goods company whose products can be found in over 95% of Brazilian homes. This milestone marks a new phase in Ypê’s AI-first vision to build a frictionless company that delivers exceptional experiences for employees, customers and stakeholders. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260127970457/en/ Ypê Deepens Partnership with Rimini Street to Accelerate Agentic AI and Maximize ERP Value Building the Foundation for Innovation Starts with Support A Rimini Support™ client for its SAP S/4HANA system, Ypê is leveraging Rimini St
PQE Group Reports Solid Year-End Results, Strengthens Position through Innovation in Pharmaceuticals and Medical Devices27.1.2026 15:00:00 CET | Press release
Revenue gains, global expansion, industry recognition, and ESG leadership supported continued growth in 2025 2025 represented another successful year for PQE Group, a consulting firm in the Life Sciences industry based in Florence (Italy) that includes more than 2000 employees and 40+ offices worldwide. Recently named "Best Managed Company" by Deloitte Private for the sixth consecutive year, the Group achieved a rise in revenue, which reached € 105 millions in 2025, an increase of 7% compared to the €97,5M millions realized in 2024. Founded by CEO Gilda D'Incerti in 1998, PQE Group is a women-owned company that has received numerous industry certifications, including ISO/IEC 27001, which is the world's best-known standard for information security, and ISO 9001, which focuses on quality management systems. To enhance its ongoing global expansion efforts, in 2025 PQE further expanded in the APAC Region, continued to strengthen its presence in North America, and established new offices in
Indero CRO and the World Scleroderma Foundation Announce Strategic Collaboration to Advance Early Therapeutic Intervention in Systemic Sclerosis27.1.2026 15:00:00 CET | Press release
Indero is pleased to announce a strategic collaboration with the World Scleroderma Foundation (WSF) to support WSF SHIELD platform trial, a randomized, double-blind, adaptive platform clinical trial designed to evaluate multiple investigational medicinal products (IMPs) for patients meeting VEDOSS criteria. This trial aims to intervene at the earliest stages of systemic sclerosis to improve long-term patient outcomes. This partnership brings together 2 leaders in their respective fields, Indero in clinical trial operations and WSF in Scleroderma research and advocacy, to create a powerful platform for innovation in rheumatology. The WSF SHIELD platform is led by Professor Francesco Del Galdo (Chair) and Professor Dinesh Khanna (Co-PI), with Professor Marco Matucci and Professor Yannick Allanore serving as WSF representatives on the steering committee. For pharmaceutical sponsors and biotech companies, this collaboration represents a unique opportunity to engage with a research initiati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom